Notably, T-VEC (talimogene laherparepvec, formerly known as OncoVEX GM-CSF), an oncolytic herpes simplex virus type 1, was acknowledged and approved by the FDA (U.S. Food and Drug Administration) in October 2015 for the treatment of inoperable melanoma, and was later approved in Europe and Australia in 2016. The gene discussed is CSF2; the disease is melanoma.